Xenetic Biosciences, Inc

(NASDAQ:XBIO)

Latest On Xenetic Biosciences, Inc (XBIO):

Date/Time Type Description Signal Details
2023-05-16 20:33 ESTNewsXenetic Bio cut to Neutral at H.C. Wainwright on lack of catalystsN/A
2023-05-12 16:22 ESTNewsXenetic Biosciences announces reverse stock split of common stockN/A
2023-03-23 09:59 ESTNewsXenetic Biosciences reports FY resultsN/A
2023-01-17 13:42 ESTNewsXenetic rises ~10% on upcoming Canadian patent for methods to improve cancer therapyN/A
2022-11-11 01:24 ESTNewsXenetic Biosciences GAAP EPS of -$0.06, revenue of $411.95MN/A
2022-08-12 10:01 ESTNewsXenetic Biosciences reports Q2 resultsN/A
2022-08-02 22:54 ESTNewsXenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancerN/A
2022-07-07 20:36 ESTNewsXenetic inks clinical manufacturing contract with CatalentN/A
2022-04-27 13:51 ESTNewsXenetic stock rises 10% on license deal for CLS Therapeutics' cancer drugs platformN/A
2022-03-23 17:58 ESTNewsXenetic Biosciences GAAP EPS of -$0.55, revenue of $1.16MN/A
2021-11-12 11:17 ESTNewsXenetic Biosciences EPS misses by $0.01, beats on revenueN/A
2021-09-09 14:39 ESTNewsXenetic Bio secures new U.S. patent for CAR T platform technologyN/A
2021-08-13 23:42 ESTNewsXenetic Biosciences EPS beats by $0.03, beats on revenueN/A
2021-07-26 07:43 ESTNewsXenetic Biosciences rallies 45% on $12.5M private placementN/A
2021-07-24 03:05 ESTNewsXenetic Biosciences more than doubles in value to reach two-year highN/A
2021-03-29 20:21 ESTNewsXenetic Biosciences shares rise on approval to start XCART exploratory studyN/A
2021-03-18 13:55 ESTEarnings EstimateAn EPS average of -$0.13 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-18 13:55 ESTEarnings EstimateAn EPS average of -$0.13 is estimated for the quarter ending on March 31, 2021.Buy
2021-03-17 14:13 ESTEarnings EstimateAn EPS average of -$0.50 is estimated for the 2022 year.Sell
2021-01-12 01:03 ESTAnalyst RatingThe Analyst Target Price has increased from $2.25 to $3.75.Buy
2020-12-10 20:48 ESTNewsXenetic Biosciences launches $6M registered direct offering priced at-the-marketN/A
2020-12-10 03:08 ESTNewsXenetic soars after PolyXen data from late-stage study in kidney disease-related anemiaN/A
2020-11-26 22:08 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 09:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-22 19:07 ESTFinancialsCompany financials have been released.Neutral
2020-11-18 13:49 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 13:45 ESTNewsXenetic Biosciences reports Q3 resultsN/A
2020-11-08 01:21 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:37 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 14:37 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 06:42 ESTFinancialsCompany financials have been released.Neutral
2020-08-15 10:01 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 10:37 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 05:44 ESTNewsXenetic Biosciences EPS beats by $0.07, beats on revenueN/A
2020-08-06 09:58 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 18:22 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 06:19 ESTFinancialsCompany financials have been released.Neutral
2020-07-29 22:28 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 14:13 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 18:56 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 10:27 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 18:12 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 14:06 ESTFinancialsCompany financials have been released.Neutral
2020-06-16 16:52 ESTNewsXenetic Bio up 8% on XCART dealN/A
2020-06-14 06:09 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 07:43 ESTFinancialsCompany financials have been released.Neutral
2020-06-02 06:17 ESTEarnings EstimateAn EPS average of -$0.40 is estimated for the quarter ending on September 30, 2020.Sell
2020-06-02 06:17 ESTEarnings EstimateAn EPS average of -$0.38 is estimated for the quarter ending on June 30, 2020.Sell
2020-06-02 06:17 ESTAnalyst RatingThe Analyst Target Price has decreased from $2.5 to $2.25.Neutral
2020-05-27 06:46 ESTFinancialsCompany financials have been released.Neutral

About Xenetic Biosciences, Inc (XBIO):

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

XBIO Quotes by TradingView

See Advanced Chart

General

  • Name Xenetic Biosciences, Inc
  • Symbol XBIO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 4
  • Last Split Factor1:12
  • Last Split Date2019-06-25
  • Fiscal Year EndDecember
  • IPO Date2014-06-30
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.xeneticbio.com
View More

Valuation

  • Trailing PE 0.82
  • Price/Sales (Trailing 12 Mt.) 51.9
  • Price/Book (Most Recent Quarter) 2.82
  • Enterprise Value Revenue 50.38
  • Enterprise Value EBITDA 0.01
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Current Year EPS Estimate -$0.80
  • Next Year EPS Estimate -$0.51
  • Next Quarter EPS Estimate -$0.19
  • Operating Margin -1074%
  • Return on Assets -17%
  • Return on Equity -74%
  • Revenue 436942
  • Earnings Per Share -$12.32
  • Revenue Per Share $0.07
  • Gross Profit 436942
  • Quarterly Earnings Growth 786.7%
View More

Highlights

  • Market Capitalization 22.57 million
  • EBITDA -6153011
  • Analyst Target Price $3.75
  • Book Value Per Share $1.40
View More

Share Statistics

  • Shares Outstanding 8.75 million
  • Shares Float 7.79 million
  • % Held by Insiders 1058%
  • % Held by Institutions 0.86%
  • Shares Short 137348
  • Shares Short Prior Month 202285
  • Short Ratio 0.25
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.5
  • 52 Week High $3.84
  • 52 Week Low $0.5
  • 50 Day Moving Average 2.75
  • 200 Day Moving Average 1.71
View More

Dividends

  • Dividend Date 2019-06-25
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Xenetic Biosciences, Inc (XBIO) Dividend Calendar:

XBIO's last dividend payment was made to shareholders on June 25, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Xenetic Biosciences, Inc (XBIO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31-$0.16-$0.2020%
2020-09-302020-11-12$N/A-$1.20-$0.16-674.19%
2020-06-302020-08-12$112927-$0.15-$0.2231.82%
2020-03-312020-05-14$56749-$0.19-$0.3748.65%
2019-12-312020-03-26$17066-$0.20-$0.3847.37%
2019-09-302019-11-14$N/A-$2.67
2019-06-302019-08-14$N/A-$1.56
2019-03-312019-05-13$N/A-$6.45
2018-12-312019-03-29$N/A-$2.09
2018-09-302018-11-09$N/A-$2.31
2018-06-302018-08-10$N/A-$2.78
2018-03-312018-05-15$N/A-$2.51
2017-12-312018-03-30$7.5 million$6.12
2017-09-302017-11-14$85000-$3.12-$4.9236.59%
2017-06-302017-08-14$N/A-$4.08-$4.6812.82%
2017-03-312017-05-15$N/A-$4.08-$2.52-61.9%
2016-12-312017-03-31$3 million-$3.60-$2.28-57.89%
2016-09-302016-11-07$N/A-$3.30-$0.19-1637.21%
2016-06-302016-06-30$N/A-$73.45
2016-03-312016-03-31$N/A-$9.34
2015-12-312015-12-31$N/A-$9.49
2015-09-302015-09-30$N/A-$15.10
2015-06-302015-06-30$N/A-$3.20
2015-03-312015-03-31$N/A-$6.91
2014-12-312014-12-31$N/A-$12.23
2014-09-302014-09-30$N/A-$9.26
2014-06-302014-06-30$N/A-$8.03
2014-03-312014-03-31$N/A-$11.83
2013-06-302013-08-31-$2.23
2013-03-312013-05-31-$0.40
2012-12-312013-02-28$0.44
2012-09-302012-11-30-$0.42
2012-06-302012-08-31-$1.50

Xenetic Biosciences, Inc (XBIO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Xenetic Biosciences, Inc (XBIO) Chart:

Xenetic Biosciences, Inc (XBIO) News:

Below you will find a list of latest news for Xenetic Biosciences, Inc (XBIO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Xenetic Biosciences, Inc (XBIO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest XBIO Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$0.6649
Jun 13, 2022 7:59 PM EST100$0.6649
Jun 13, 2022 7:59 PM EST300$0.6649

Xenetic Biosciences, Inc (XBIO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316820002051/0001683168-20-002051-index.htm
2019-09-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1534525/000000000019013737/0000000000-19-013737-index.htm
2020-01-21SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1534525/000090266420000308/0000902664-20-000308-index.htm
2019-10-23SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1534525/000094480919000072/0000944809-19-000072-index.htm
2019-08-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1534525/000110465919044521/0001104659-19-044521-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1534525/000110465920013384/0001104659-20-013384-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1534525/000119312520038180/0001193125-20-038180-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1534525/000138713120001537/0001387131-20-001537-index.htm
2019-09-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1534525/000153561019000095/0001535610-19-000095-index.htm
2020-01-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1534525/000153561020000031/0001535610-20-000031-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1534525/000168316819002639/0001683168-19-002639-index.htm
2019-08-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316819002648/0001683168-19-002648-index.htm
2019-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316819002876/0001683168-19-002876-index.htm
2019-09-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1534525/000168316819002928/0001683168-19-002928-index.htm
2019-09-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1534525/000168316819002980/0001683168-19-002980-index.htm
2019-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003103/0001683168-19-003103-index.htm
2019-09-303Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003105/0001683168-19-003105-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003106/0001683168-19-003106-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003107/0001683168-19-003107-index.htm
2019-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003199/0001683168-19-003199-index.htm
2019-11-08DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003504/0001683168-19-003504-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1534525/000168316819003653/0001683168-19-003653-index.htm
2019-11-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003668/0001683168-19-003668-index.htm
2019-12-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003909/0001683168-19-003909-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003911/0001683168-19-003911-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003913/0001683168-19-003913-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003915/0001683168-19-003915-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003917/0001683168-19-003917-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003919/0001683168-19-003919-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003921/0001683168-19-003921-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1534525/000168316819003923/0001683168-19-003923-index.htm
2020-03-2610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1534525/000168316820000967/0001683168-20-000967-index.htm
2020-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316820000973/0001683168-20-000973-index.htm
2020-04-01S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1534525/000168316820001062/0001683168-20-001062-index.htm
2020-04-024/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1534525/000168316820001069/0001683168-20-001069-index.htm
2020-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316820001278/0001683168-20-001278-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1534525/000168316820001321/0001683168-20-001321-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316820001564/0001683168-20-001564-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1534525/000168316820001566/0001683168-20-001566-index.htm
2020-05-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316820001661/0001683168-20-001661-index.htm
2020-06-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316820001954/0001683168-20-001954-index.htm
2020-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316820002051/0001683168-20-002051-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1534525/000168316820002645/0001683168-20-002645-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316820002655/0001683168-20-002655-index.htm
2020-09-30PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1534525/000168316820003318/0001683168-20-003318-index.htm
2020-10-13DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1534525/000168316820003429/0001683168-20-003429-index.htm
2020-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1534525/000168316820003619/0001683168-20-003619-index.htm
2019-09-23EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1534525/999999999519002156/9999999995-19-002156-index.htm